CytomX Therapeutics Inc (NASDAQ: CTMX) kicked off on Monday, down -4.60% from the previous trading day, before settling in for the closing price of $0.78. Over the past 52 weeks, CTMX has traded in a range of $0.75-$5.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 36.16%. While this was happening, its average annual earnings per share was recorded -326.46%. With a float of $76.25 million, this company’s outstanding shares have now reached $78.23 million.
Let’s determine the extent of company efficiency that accounts for 122 employees. In terms of profitability, gross margin is 98.88%, operating margin of 5.3%, and the pretax margin is 11.89%.
CytomX Therapeutics Inc (CTMX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc is 2.56%, while institutional ownership is 59.78%. The most recent insider transaction that took place on Aug 20 ’24, was worth 5,139. In this transaction Chief Business Officer of this company sold 4,181 shares at a rate of $1.23, taking the stock ownership to the 119,056 shares. Before that another transaction happened on Aug 20 ’24, when Company’s SVP, Chief Scientific Officer sold 4,181 for $1.23, making the entire transaction worth $5,139. This insider now owns 175,648 shares in total.
CytomX Therapeutics Inc (CTMX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -326.46% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Take a look at CytomX Therapeutics Inc’s (CTMX) current performance indicators. Last quarter, stock had a quick ratio of 1.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.17, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Looking closely at CytomX Therapeutics Inc (NASDAQ: CTMX), its last 5-days average volume was 0.63 million, which is a drop from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 38.24%. Additionally, its Average True Range was 0.06.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 6.84%, which indicates a significant decrease from 17.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.35% in the past 14 days, which was higher than the 68.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9407, while its 200-day Moving Average is $1.2306. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $0.7880. Second resistance stands at $0.8320. The third major resistance level sits at $0.8787. If the price goes on to break the first support level at $0.6973, it is likely to go to the next support level at $0.6506. Should the price break the second support level, the third support level stands at $0.6066.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
The company with the Market Capitalisation of 58.23 million has total of 78,259K Shares Outstanding. Its annual sales at the moment are 101,210 K in contrast with the sum of -570 K annual income. Company’s last quarter sales were recorded 33,430 K and last quarter income was 5,740 K.
